Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinom
Go back to Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinom| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 58.49 +1.71 (3.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $56.78 | 52 Week High | $17.00 | |||
| Open | $57.23 | 52 Week Low | $3.55 | |||
| Day High | $58.52 | P/E | N/A | |||
| Day Low | $57.23 | EPS | $-1.33 | |||
| Volume | 1,785,586 | |||||
